These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26210060)

  • 1. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.
    Volk DW; Lewis DA
    Biol Psychiatry; 2016 Apr; 79(7):595-603. PubMed ID: 26210060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study.
    Chou S; Fish KN; Lewis DA; Sweet RA
    Neurobiol Dis; 2023 Sep; 185():106262. PubMed ID: 37586566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction.
    Laviolette SR; Grace AA
    Cell Mol Life Sci; 2006 Jul; 63(14):1597-613. PubMed ID: 16699809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex.
    Eggan SM; Mizoguchi Y; Stoyak SR; Lewis DA
    Cereb Cortex; 2010 May; 20(5):1164-74. PubMed ID: 19703937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study.
    Chou S; Fish KN; Lewis DA; Sweet RA
    bioRxiv; 2023 Apr; ():. PubMed ID: 37090672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Rbfox1-Vamp1 pathway and prefrontal cortical dysfunction in schizophrenia.
    Chung Y; Dienel SJ; Belch MJ; Fish KN; Ermentrout GB; Lewis DA; Chung DW
    Mol Psychiatry; 2024 May; 29(5):1382-1391. PubMed ID: 38273110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laminar Distribution of Cannabinoid Receptor 1 in the Prefrontal Cortex of Nonhuman Primates.
    Han Y; Dong Q; Peng J; Li B; Sun C; Ma C
    Mol Neurobiol; 2024 Jul; 61(7):1-12. PubMed ID: 38062346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases.
    Ma L; Wu S; Zhang K; Tian M; Zhang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 50(5):666-673. PubMed ID: 34986538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoid signaling in the etiology and treatment of major depressive illness.
    Hillard CJ; Liu QS
    Curr Pharm Des; 2014; 20(23):3795-811. PubMed ID: 24180398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No additive effect of cannabis on cognition in schizophrenia.
    Power BD; Dragovic M; Badcock JC; Morgan VA; Castle D; Jablensky A; Stefanis NC
    Schizophr Res; 2015 Oct; 168(1-2):245-51. PubMed ID: 26235754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.
    Scherma M; Muntoni AL; Melis M; Fattore L; Fadda P; Fratta W; Pistis M
    Psychopharmacology (Berl); 2016 May; 233(10):1765-77. PubMed ID: 26728894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tetrahydrocannabinol on arterial and intraocular hypertension.
    Crawford WJ; Merritt JC
    Int J Clin Pharmacol Biopharm; 1979 May; 17(5):191-6. PubMed ID: 468444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.
    Kozela E; Juknat A; Gao F; Kaushansky N; Coppola G; Vogel Z
    J Neuroinflammation; 2016 Jun; 13(1):136. PubMed ID: 27256343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids: Medical implications.
    Schrot RJ; Hubbard JR
    Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prescription of medical cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: a case report.
    Meng H; Hanlon JG; Katznelson R; Ghanekar A; McGilvray I; Clarke H
    Can J Anaesth; 2016 Mar; 63(3):307-10. PubMed ID: 26507533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal Cannabis: A Survey Among Health Care Providers in Washington State.
    Carlini BH; Garrett SB; Carter GT
    Am J Hosp Palliat Care; 2017 Feb; 34(1):85-91. PubMed ID: 26377551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling.
    Anderson GR; Aoto J; Tabuchi K; Földy C; Covy J; Yee AX; Wu D; Lee SJ; Chen L; Malenka RC; Südhof TC
    Cell; 2015 Jul; 162(3):593-606. PubMed ID: 26213384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.
    Viader A; Blankman JL; Zhong P; Liu X; Schlosburg JE; Joslyn CM; Liu QS; Tomarchio AJ; Lichtman AH; Selley DE; Sim-Selley LJ; Cravatt BF
    Cell Rep; 2015 Aug; 12(5):798-808. PubMed ID: 26212325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Anxiolytic Actions of 2-Arachidonoylglycerol: Converging Evidence From Two Recent Genetic Endocannabinoid Deficiency Models.
    Patel S; Shonesy BC; Bluett RJ; Winder DG; Colbran RJ
    Biol Psychiatry; 2016 May; 79(10):e78-e79. PubMed ID: 26212898
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterizing substance use and mental health profiles of cigar, blunt, and non-blunt marijuana users from the National Survey of Drug Use and Health.
    Cohn A; Johnson A; Ehlke S; Villanti AC
    Drug Alcohol Depend; 2016 Mar; 160():105-11. PubMed ID: 26803718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.